Drug checking as a harm reduction tool for recreational drug users: opportunities and challenges. by Brunt, Tibor
Author
T. Brunt
2017
Drug checking as a harm reduction 
tool for recreational drug users: 
opportunities and challenges
Background paper commissioned by the EMCDDA for 
Health and social responses to drug problems: a European guide
  
Drug checking as a harm reduction tool for recreational drug users: 
opportunities and challenges 
 
Dr Tibor Brunt 
Drug Information and Monitoring System, the Netherlands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
October 2017 
 
This paper was commissioned by the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) to provide background information to inform and 
contribute to the drafting of Health and social responses to drug problems: a 
European guide.  
This background paper was produced under contract CT.16.SDI.0147.1.0 and we are 
grateful for the valuable contribution of the author. The paper has been cited within 
Health and social responses to drug problems and is also being made available 
online for those who would like further information on the topic. However, the views, 
interpretations and conclusions set out in this publication are those of the author and 
are not necessarily those of the EMCDDA or its partners, any EU Member State or 
any agency or institution of the European Union. 
 
  
 3 
 
 
 
1. Introduction 
The use of illicit drugs is an ongoing political, legal, economic and health issue. The 
use of most illicit drugs poses several health risks, which can lead to problems and 
the need for medical treatment. To mitigate these health problems, most European 
countries have prohibited (non-prescription) drugs of abuse under international 
conventions (UNODC, 2013). These treaties are directed at the prohibition of the 
manufacture, distribution and possession of listed substances. This strategy is also 
referred to as the ‘supply reduction’ approach in drug policy (Caulkins and Reuter, 
1997). Alongside this effort, some European countries have also adopted more 
pragmatic drug policies, which acknowledge that illicit drugs will be used despite legal 
attempts to limit their availability. Such policies aim to reduce harm to users and 
society by offering specialised services to drug users, referred to as the ‘harm 
reduction’ approach (Marlatt et al., 2012). A good example of a harm reduction 
strategy is syringe exchange programmes, which originated in 1984 in Amsterdam as 
a measure to stop the spread of the hepatitis B virus and the human 
immunodeficiency virus (HIV) among injecting drug users and has since been 
adopted globally in an attempt to prevent the transmission of viral blood-borne 
diseases in this group and their social environment (Hartgers et al., 1989). Other 
examples of harm reduction approaches include heroin-assisted treatment and safe 
injection rooms for chronic, often treatment-refractory, drug users (Kerr et al., 2007; 
Blanken et al., 2010). 
 
Originally, syringe exchange programmes and injection rooms were principally aimed 
at problematic, marginalised drug users. However, the drug users that have followed 
in the slipstream of the electronic dance music revolution of the early 1990s and 
changing nightlife settings are not characterised by high unemployment or major 
problems in other areas. Rather, most people who use drugs in such recreational 
settings have relatively few drug-related problems and do not differ much from those 
who do not use drugs, except for their predilection for nightlife and a hedonistic 
lifestyle (Tossmann et al., 2001; Butler and Montgomery, 2004). In western Europe, 
this trend is characterised by the increasing popularity of many stimulant drugs that 
boost energy and self-confidence (Boys et al., 2001). These include both well-known 
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illicit drugs and novel stimulants. In addition, novel psychedelics have also regained 
popularity, especially among the young and highly educated, whose reason for using 
drugs is typically to expand their horizons (Orsolini et al., 2015). The often unknown 
nature of these substances and the settings in which they are taken, such as 
crowded nightclubs or large and densely populated dance events, bring their own 
specific risks. So, in contrast to chronic and compulsive drug use, treatment of which 
addresses dependence and withdrawal, an incidental (or recreational) pattern of drug 
use might necessitate the treatment of acute intoxication symptoms. The goal of 
reducing acute harms among drug users at dance events and clubs has led to the 
spread worldwide of initiatives such as the provision of good ventilation, accessible 
drinking water and chill-out spots and the presence of first aid teams in such settings 
(Bellis et al., 2002). In addition, because, in many cases, the dose and contents of 
these substances are unknown, and because users are unfamiliar with the effects of 
many of these substances, additional harm reduction initiatives directed at 
recreational users, such as drug-testing (or drug-checking) services (Spruit, 1999; 
Kriener et al., 2001; Spruit, 2001), have been developed. 
 
2. The history and expansion of the drug-checking provision across Europe 
The use of ecstasy (3,4-methylenedioxymethamphetamine (MDMA)) and related 
phenethylamines, but also GHB (gamma-hydroxybutyrate) or ketamine, is associated 
with effects and risks different from those associated with traditional illicit substances, 
such as cocaine and heroin. The risks associated with these substances have led to 
drug checking (or testing) being introduced to the nightlife setting as a harm reduction 
strategy across Europe and the United States. In 1992, in the Netherlands, the 
Ministry of Health decided to fund the first drug-checking system in Europe, the Drug 
Information and Monitoring System (DIMS), housed at the Trimbos Institute (Spruit, 
1999). DIMS was established as a scientific project to monitor new and existing drug 
markets with respect to dose, composition, adulterants and availability. It is a 
nationwide system of stationary testing facilities, embedded in different regional 
institutes of prevention and addiction care (for an elaborate description of methods, 
see Brunt and Niesink, 2011). It closely mirrors a system of pharmacovigilance and 
also reports collected data to the European Union (EU) Early Warning System (EWS) 
(EMCDDA and Europol, 2007). 
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Following in the footsteps of this Dutch initiative, drug-checking systems have been 
set up by other countries in western Europe. In Austria, a mobile onsite drug-
checking service (Check It) was set up in 1997, supported by the municipality of 
Vienna and the Austrian government (Kriener et al., 2001). In 2001, the Swiss also 
introduced a similar mobile testing unit, funded by the municipality of Zürich (Bücheli 
et al., 2010). In Belgium, funded by the municipality of Wallonia-Brussels, a small-
scale drug-testing initiative started in 1993 (Modus Vivendi). In Spain, a simple on-
site drug-testing initiative started in 1997. Subsequently, a stationary testing facility, 
Energy Control, incorporating advanced chemical analysis techniques, partly 
financed by the government, was established (Energy Control, 2017). Drug samples 
collected throughout Spain can be sent to this facility. The late 1990s also saw the 
establishment, in France, of SINTES (National Detection System of Drugs and Toxic 
Substances), which allows drug samples collected voluntarily from drug users at any 
location to be sent to an analytical forensic chemical laboratory (Giraudon and Bello, 
2007). In 2001, a Portuguese on-site drug-testing service (Check !n) was introduced 
at festivals, partly funded by the government (Martins et al., 2015). Most recently, in 
2009, Wales introduced a drug-testing initiative called WEDINOS, which is financed 
by the United Kingdom National Health Service (NHS Wales, 2015). Users can 
anonymously send in drug samples and receive test results online. Outside Europe, 
in the United States, a small-scale drug-testing system (DanceSafe) enables the 
results of the analysis of ecstasy pills to be shared on the internet (Tanner-Smith, 
2006). In addition, several other European countries are considering drug-testing 
services or have already started to offer such services (Figure 1). 
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Figure 1 
European drug-checking services in existence in 2017 
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3. The types of drug-checking services available and their pros and cons 
Although most drug-checking services have been adopted for harm reduction 
purposes, they operate individually, and the chemical drug analysis techniques used 
vary considerably. An international collaborative effort between 2011 and 2013, the 
Trans European Drug Information (TEDI) project, combined data from the drug-
checking systems of Spain, Switzerland, Belgium, Austria, Portugal and the 
Netherlands to compare results and exchange knowledge about the different analysis 
techniques used (Brunt et al., 2017). In summary, based on the available funds, the 
techniques used vary from colorimetric reagents (not expensive, but inaccurate) to 
advanced gas chromatography (GC) coupled to mass spectrometry (GC/MS), GC 
coupled to mass spectrometry coupled to mass spectrometry (GC/MS/MS) or GC 
coupled to quantitative time-of-flight mass spectrometry (GC/QToF/MS) (expensive 
and very accurate). However, the laboratory techniques used are also dependent on 
the setting.  
 
Stationary testing facilities, for example a certified immobile laboratory, are able to 
put a whole range of advanced chemical analysis techniques at the disposal of the 
drug-checking service. However, some drug-checking services (e.g. Check It, 
Austria; Safer Dance, Switzerland; Check !n, Portugal) aim to test drugs on the spot 
in clubs or at dance events and to immediately communicate the results to 
consumers. In such cases, it is usually not possible to provide extensive, state-of-the-
art laboratory facilities. For this reason, Check It and Safer Dance make use of 
mobile high-performance liquid chromatography (HPLC) devices. However, a back-
up laboratory is available to further analyse samples if a compound is not adequately 
identifies by HPLC alone. An overview of TEDI’s drug-checking services and the 
corresponding laboratory techniques used is given in Table 1. 
  
 8 
 
Table 1. Different laboratory methods used by a sample of European drug-testing 
services that are part of the TEDI project 
 
Method 
Drug-testing service 
Check !n 
(Portugal) 
Energy 
Control 
(Spain) 
DIMS 
(Netherlands) 
Safer Dance 
(Switzerland) 
Check It 
(Austria)a 
TLC X X — — — 
LC/ESI/QToF — X
b — — — 
LC/ESI/MS/MS — X — — — 
LC/ESI/MS — X X — — 
LC/DAD — — X X X 
GC/FID — — X — — 
GC/MS — X X X X 
GC/MS/MS — — X X X 
NMR — Xb X
b — Xb 
HPLC — X — X X 
 
Notes: For further descriptions of these techniques, see Brunt et al. (2017). 
(a) Check It works in close collaboration with a laboratory that uses more elaborate laboratory methods. 
(b) Only when requested for specialised analysis.  
DAD, diode array detection; ESI, electrospray ionisation; FID, flame ionisation detection; NMR, nuclear magnetic 
resonance; TLC, thin-chromatography. 
 
The nature of a drug-checking service affects the accuracy and reliability of the 
analysis results and, therefore, the extent of harm reduction. Simply put, do you 
merely want to demonstrate the presence or absence of a main component in a drug 
sample or do you want to provide quantitative information about all compounds in a 
drug sample to a consumer? Existing drug-checking services offer either of these two 
extreme options or a service somewhere in between, depending on the available 
funds, the goals and the type of service provided (or allowed). An overview of the 
different types of drug-checking services and the implications for testing reliability and 
accuracy, preventive function and the potential for harm reduction is given in 
Figure 2. 
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Figure 2 
General utility of current types of drug-testing methods used 
 
 
 
 
Finally, the specific aims can differ across the different drug-testing agencies. DIMS 
is primarily a monitoring instrument that aims to gain information about the drug 
market for policy purposes and surveillance. This could result in either targeted 
warnings to a specific user group or mass media campaigns aimed at the general 
public in the case of compounds that pose additional risks, which depends on toxicity 
information and the potential geographical spread of the drugs in question. Most 
other systems publish all of their analysis results on information boards at dance 
events (Check It and Safer Dance) or post them online for all potential drug users to 
read (DanceSafe: www.ecstasy.org). In addition, depending on the system, warnings 
are issued nationally or internationally (e.g. to the EWS). What is considered to be a 
hazardous content of a drug sample by one system might not automatically be 
considered hazardous by another. Finally, Energy Control recently piloted a project 
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whereby drugs purchased by consumers on cryptomarkets (1) could be submitted for 
analysis (Caudevilla et al., 2016). The results were anonymously reported back to the 
consumer. Figure 3 gives a brief summary of some of the methodologies used, the 
aims and types of interventions, and how these are linked to the drug-checking 
results. 
 
Figure 3 
Ways in which drug checking services can vary 
 
 
3.1 Pros: an efficient strategy to promote the health of and reduce harms to drug users 
How can drug checking help to reduce harm related to drug use? Firstly, it is 
important to bear in mind that many drug-checking initiatives were introduced with the 
aim of extending prevention activities to young recreational drug users, a group that 
was not being reached by many national institutions for prevention and addiction 
care. Traditionally, most of those institutions either were specialised in prevention on 
a broader societal level or directed harm reduction activities towards problematic and 
marginalised groups of drug users. By introducing drug checking, such institutions 
found a way of establishing contact with the emerging group of young, recreational 
drug users with the aim of providing prevention and harm reduction activities. Drug-
checking systems, with their guaranteed anonymity and confidentiality, are 
considered trustworthy by many young recreational drug users, as individual harm 
                                          
(1) A cyptomarket is a marketplace that hosts multiple sellers or ‘vendors’, is located on the hidden web (dark web 
or dark net) and uses cryptocurrencies (e.g. Bitcoin) for payment, providing participants with an anonymous way 
of purchasing goods, legal or illegal. 
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reduction advice potentially serves the needs of this group better than simple 
promotion of complete abstention (Gamma et al., 2005; Fernández-Calderón et al., 
2014). 
 
Secondly, government-advocated messages, often viewed as scare tactics, are 
considered tendentious and untrustworthy, and conflict with the individual’s idea of 
self-regulation (Ritter, 2010). Personal contacts with well-informed peers or 
professionals employed by drug-checking services are believed to be much more 
effective at persuading drug users to pay attention to preventive information and 
change their behaviour positively (Allott et al., 1999; Falck et al., 2004; Toumbourou 
et al., 2007). In addition, drug checking might serve as an immediate intervention tool 
to change an individual’s drug use if drugs are shown to contain unwanted or 
unknown chemical compounds (Johnston et al., 2006; Fernández-Calderón et al., 
2014). 
 
3.2 Criticism: cons of the different types of drug-checking services 
Although there are arguments in favour of drug checking, the strategy has also met 
with much criticism. For instance, it could give drug users an unjustified feeling of 
safety about the drugs they are taking: the absence of unexpected or acute 
toxicological compounds in no way guarantees that a drug is safe (Winstock et al., 
2001). Every form of drug use is potentially hazardous, and there is no way to 
completely eradicate the risk. However, when drug checking is thoroughly embedded 
in a prevention unit, staff have to the opportunity to communicate scientific 
information about the test results and educate users about general drug risks, 
thereby eliminating this false sense of security.  
 
It is also important to bear in mind that there are different types of drug-checking 
services (Figures 2 and 3). Although on-site drug checking might very well work in 
terms of transferring warnings and offering prevention advice, even entailing 
counselling or motivational interviewing, the noisy atmosphere at large venues is 
often a challenge, reducing the effectiveness of this tactic. Moreover, users in such 
settings might already be under the influence of substances. For this reason, in the 
Netherlands, drug checking at stationary offices has become the usual practice, often 
on uneventful weekdays. This gives prevention professionals the opportunity to 
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speak with drug users in a quiet environment, and provides possibilities for 
motivational counselling. In fact, nowadays, many young drug users seem to 
purchase drugs from alternative sources, rather than from dealers at events (Global 
Drug Survey, 2016), making it possible for them to have their drugs tested before 
consumption at such events. Another practical drawback of onsite drug-checking 
services that use crude and inaccurate ‘quick tests’ is that such tests often lead to 
unreliable or meaningless results, which nullify the harm reduction function. 
 
It could also be argued that drug testing might be misused by vendors or dealers, by 
providing them with information about purity which they can use to promote their 
products. Although proper scientific evidence for this is lacking, one DIMS study 
found that drug-testing results are often published on the internet (e.g. 
www.pillreports.net, www.partyflock.nl) to inform others about the purity or chemical 
contents of certain pills (Vrolijk et al., 2017). The possibility that the reason for 
publishing this information is in fact to promote and sell products cannot be excluded. 
 
It has previously been suggested that drug users will consume the drugs they have 
purchased regardless of the analysis outcome (Winstock et al., 2001). This argument 
is refuted by studies reporting that 25 to 100 % of drug users will discard their drugs if 
they learn that they contain unwanted or unexpected harmful compounds (Stevens, 
2017; Measham, in press). However, when considering this finding, the type of drug-
testing service should also be taken into account. It seems a valid argument that on-
site testing might not prevent people from using questionable drugs, since in this 
case the user is already at a dance event or a club and will have less opportunity to 
obtain other drugs in the event of an unexpected result. 
 
Another common criticism is that drug testing encourages young people to take 
drugs, or to take more drugs than they would if such services were not available. This 
criticism appears to be unfounded, and, in fact, it has been shown that drug use does 
not increase following the introduction of a drug-testing service in a country (Bücheli 
et al., 2010). In addition, the prevalence of drug use does not seem to be higher in 
countries that have drug-checking systems in place (EMCDDA, 2016). In addition, 
previous research has shown that drug users who use testing services do not use 
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more drugs than drug users who do not do so (Benschop et al., 2002). In fact, the 
same study also found that the presence of drug-checking services did not 
encourage those who do not use drugs to begin drug use. 
 
4. Can drug checking save lives? 
Another interesting question that has been raised is whether or not drug checking 
can save lives. Over the years, there have been cases of certain batches of drugs 
containing lethal substances causing deaths in countries without a drug-checking 
service, but not in countries with a drug-checking service that issues public warnings. 
For example, DIMS recently reported that each of a batch of pink pills bearing a 
Superman logo contained 170 mg of PMMA (para-methoxymetamphetamine), an 
unpredictable compound, and one much more toxic compound than MDMA. In the 
Netherlands and Belgium, this immediately led to national mass media warning 
campaigns that included national radio and television broadcasts, posts on social 
media and on the internet, and flyers and posters at large dance events (Keijsers et 
al., 2008). The Healthy Nightlife Network (prevention professionals, peer coaches) 
and first aid professionals were also informed. In the United Kingdom, however, 
where no drug-checking system was in place at the time, the same pills caused the 
death of four young people (Hill, 2015). This led Professor David Nutt to call for drug 
checking/pill testing in the United Kingdom (Siddique, 2015). As part of their 
surveillance function, drug-checking services, by executing warning campaigns, can 
cause hazardous drugs to be quickly removed from the market, thus creating 
awareness among drug users and deterring dealers from selling the product (Spruit, 
2001). In addition, the chemical composition of illicit drugs seems to correspond more 
closely to what is expected in countries with drug-checking systems than in countries 
without such systems, suggesting that drug testing has some kind of influence on the 
illicit drug market (Kriener et al., 2001; Parrott, 2004). 
 
In recent years there has been a sharp increase in the number of new psychoactive 
substances (NPS) on the market, presenting drug-checking services with a new 
challenge (EMCDDA, 2015). The detection and quantification of unknown 
compounds presents a technical problem, requiring state-of-the-art analytical 
equipment and software. More important is the challenge of communicating the 
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results of tests of new substances with unknown effects. Here the role of the 
European Monitoring Centre for Drugs and Drug Addiction’s (EMCDDA’s) EWS is 
more important than ever, as it enables information about countless NPS to be 
quickly gathered and disseminated. Information on NPS reported to the EWS can 
readily be picked up by drug-checking systems, and European drug users can be 
quickly discouraged from taking risky NPS with the potential to cause severe harm or 
death. For instance, 5-IT (5-(2-aminopropyl)indole) was quickly withdrawn from sale 
on the internet after it became apparent that this is a deadly compound (EMCDDA, 
2014). Another dangerous phenomenon uncovered by drug-checking services is the 
presence of NPS as adulterants of commonly consumed drugs, such as MDMA, 
amphetamine or LSD (lysergic acid diethylamide) (Brunt et al., 2017; Martins et al., 
2017). 
 
5. Drug policy and the legal challenges in Europe 
Certain legal hurdles need to be overcome before a drug-checking service can be 
established; most importantly, an exemption is required to handle and analyse 
controlled substances (Home Office, 2014). Such exemptions are issued only in 
special circumstances (scientific research purposes, pharmaceutical practices or 
forensic purposes), and many countries do not recognise drug checking as a reason 
to issue such an exemption. This makes it difficult to establish a drug-checking 
service , and many attempts to set up such services have not yet surmounted this 
first jurisprudential hurdle. In addition, the possession of controlled substances is a 
legal offence in most EU Member States, which technically makes all testing drug 
users subject to punishment by the rule of law (UNODC, 2013). These are just some 
of the barriers that must be overcome to even contemplate drug testing, making it a 
very delicate subject, even in the countries where it is available. 
A favourable attitude on the part of government will certainly aid the establishment of 
a drug-checking service. Another solution adopted in some countries, such as the 
Netherlands and Austria, is to set up a drug-checking service as a scientific project 
with primarily research goals rather than as a customer service, as a way of making it 
acceptable. In the Netherlands, an official agreement with the public prosecution 
service ensures that anyone possessing illicit drugs at a DIMS drug-testing service 
will not be arrested or prosecuted (Dutch Second Chamber States General, 1999). 
This unique agreement makes the testing system possible but also has to be 
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honoured by the police. Without political support, such an arrangement would have 
been impossible.  
 
These challenges mean that in much of the world, drug testing is a daring and 
pioneering exercise, but there are signs that the winds might be changing in its favour 
(Butterfield et al., 2016; Fisher and Measham, 2016; Sage and Michelow, 2016; 
Ritter, 2017). 
 
6. The future of drug testing in Europe 
As described above, accurate drug checking and the quantification of compounds is 
still limited by the need for advanced and expensive laboratory equipment. Ideally, it 
needs a laboratory with GC/MS, gas chromatography coupled to flame ionisation 
detection (GC/FID) or HPLC at the very least (see Table 1). However, most of these 
techniques require complex sample preparation and specialised operating staff, and 
take a relatively long time and incur high costs. This automatically implies that 
accurate and reliable drug testing by a drug-checking service is heavily dependent on 
sufficient funding. As implied in the discussion about policy, above, this funding will 
usually have to come from national or regional governmental stakeholders (i.e. the 
relevant ministry or municipality governance). In fact, the criticism that the results of 
some drug-checking services are unreliable and of limited utility, which can be 
attributed to a lack of advanced drug-testing equipment, is a problem not so much of 
drug checking as of a lack of proper funding. One way of obtaining the required 
funding that could be viable would be to embed drug checking in the prevention and 
harm reduction programmes that are rolled out by most countries. This would seem 
to be a logical solution given that personalised prevention would be facilitated by 
contact between drug users and prevention specialists at drug-checking services. 
Another way of obtaining systematic funding would be to use drug checking as a 
monitoring tool to obtain drug market information, in the same way as DIMS was set 
up at the end of the 1990s. 
 
Scientific innovation may also further the cause of those who want to implement drug 
checking, as scientists have been working on simpler and cheaper methods of 
reliable drug checking. One such technique that seems to be very promising is 
infrared spectroscopy (Grobério et al., 2015; Penido et al., 2015). As most molecules 
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(e.g. cocaine or MDMA) exhibit a unique pattern (spectra) of absorption of infrared 
light, it is possible to identify accurately a large range of compounds (i.e. qualitative 
testing). In addition, quantification is possible by coupling Fourier transform infrared 
spectroscopy (FTIR) to a mathematical model that enables the proportions of 
different compounds in a sample to be determined (Grobério et al., 2015; Eliaerts et 
al., 2016). Currently, FTIR is being used in the United Kingdom by the drug-checking 
project ‘The Loop’ (http://wearetheloop.co.uk/), and DIMS is also using it for 
analyses. An additional advantage of FTIR is that compact hand-held devices have 
been developed, making possible on-site drug checking using this technique 
(Hoffmann et al., 2016). 
 
Despite promising new techniques and innovations, drug checking still faces many 
challenges posed by the developing drug market. As previously mentioned, the ever-
growing list of known NPS requires an advanced understanding of the chemical 
complexity of these substances and up-to-date spectral databases. Here, again, the 
EWS of the EMCDDA plays a pivotal role, collecting spectral data (infrared, GC/MS, 
nuclear magnetic resonance (NMR)) on most of these compounds from around the 
globe (EMCDDA and Europol, 2007). Crucial input for the EWS database is delivered 
by the different European forensic institutes and also customs laboratories, which 
provide the majority of the information. With regard to the technical limitations of 
different types of drug checking, it should be mentioned that it is not only new 
compounds that pose a challenge, but also detecting minute concentrations of known 
compounds. For instance, very low concentrations of atropine in powder cocaine, as 
has been detected in the past (Boermans et al., 2006), will not be picked up by IR or 
relatively low-resolution techniques. 
 
Finally, the behaviour of drug users is an ongoing challenge for workers at drug-
checking services. Drug checking relies heavily on the presumption that drug users 
are susceptible to harm reduction advice, yet some groups not seem susceptible to 
such advice, such as those who participate in ‘chemsex’ parties (parties at which 
people take a combination of synthetic drugs and participate in sex, popular with the 
gay and bisexual communities) (Hockenhull et al., 2017; Schmidt et al., 2016). In 
addition, harm reduction advice based on drug checking is unable to address 
polydrug use, as this is associated with risks that are far more unpredictable than 
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those of using one drug alone. For these groups, consideration should be given to 
combining drug checking and harm reduction advice with behavioural intervention 
techniques, such as counselling. 
 
7. Conclusions 
 
A number of European countries have implemented drug checking with the aim of 
providing targeted preventive messages to recreational drug users. This approach, 
which is more individualised than mass media campaigns, provides an incentive for 
drug users to participate in a dialogue about prevention and harm reduction, because 
they get to know the test results, that is they receive information about the particular 
drugs they are consuming. Pharmacovigilance in the form of drug-checking systems 
has resulted in timely warning campaigns specifically directed at groups at risk, 
conveying a level of professionalism that is appreciated by recreational drug users. 
Such an approach creates more awareness about the specific drugs that are 
consumed and the options for drug checking. By no means should these arguments 
in favour of drug testing be considered scientific evidence of its efficacy, but such 
considerations might be helpful for stakeholders deliberating whether or not to 
introduce drug testing. Complemented by other activities implemented in nightlife 
settings, such as chill-out rooms, the provision of factual and trustworthy information, 
counselling, good ventilation and other precautionary safety measures, drug 
checking can serve as an extension of prevention and harm reduction interventions, 
potentially saving lives. 
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